Diabetes Strategies for Endocrinologists-SGLT2 inhibitors: Hot Topics and Challenges

Video Transcription

Video Summary

The video features three speakers, Roma Yanchandani, Neera Rasooli, and Christine Kulasa, discussing the use of SGLT-2 inhibitors in various settings. Roma Yanchandani discusses the use of these inhibitors in the inpatient setting, reviewing the literature and presenting a case study showcasing their benefits for heart failure. Neera Rasooli focuses on the efficacy and risks of SGLT-2 inhibitors for diabetes treatment, highlighting their glucose-lowering effects and impact on cardiovascular outcomes. Christine Kulasa discusses the collaboration between non-endocrinologists and endocrinologists in using SGLT-2 inhibitors for non-diabetic patients, providing indications and strategies for successful collaboration.<br /><br />The speakers emphasize the growing use of SGLT-2 inhibitors in hospitals and their benefits in terms of glucose control, cardiovascular outcomes, and heart failure management. They also address potential side effects and the importance of monitoring and addressing them. The video sheds light on current research and clinical use of these inhibitors, highlighting their potential to improve patient outcomes.<br /><br />In addition, the video mentions that SGLT-2 inhibitors have shown positive effects in patients with chronic kidney disease, reducing the risk of composite endpoints. The potential side effects discussed include ketoacidosis, amputation, genital mycotic infections, and urinary tract infections. Strategies for monitoring and managing these side effects are also discussed.<br /><br />The speakers underscore the need for collaboration between healthcare professionals in incorporating SGLT-2 inhibitors into patient management. They suggest new models of care and training programs to facilitate this collaboration and optimize patient care.<br /><br />Overall, the video provides valuable insights into the use of SGLT-2 inhibitors in different settings, their benefits, potential side effects, and the importance of collaboration to maximize their effectiveness.

Keywords

SGLT-2 inhibitors

Roma Yanchandani

Neera Rasooli

Christine Kulasa

inpatient setting

heart failure

diabetes treatment

glucose-lowering effects

cardiovascular outcomes

non-diabetic patients

collaboration between healthcare professionals